Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study

Funding Agencies|Roche Sweden AB [ML22754]
There have been concerns about serious infusion-related adverse drug reactions (ADR) with rituximabin chronic lymphocytic leukemia (CLL). We therefore conducted an observational trial in which CLL patients planned for rituximab-containing therapy were eligible. Ninety-six patients from 19 centers were enrolled. The most common regimen was rituximab, fludarabine and cyclophosphamide. Fifty-six patients experienced ADR during rituximab infusion. Reactions greater than= grade 3 occurred in five patients and no cases of tumor lysis syndrome were recorded. Despite a high number of circulating tumor cells few severe ADR were noted. Thus, rituximab containing regimens can be considered safe for CLL patients in general practice.

Bjorkstrand, BoKarolinska University Hospital, Sweden; Karolinska Institute, Sweden (författare)
Rommel, FranzRegion Östergötland, Hematologiska kliniken US (författare)
Timberg, LarsKristianstad Central Hospital, Sweden (författare)
Andersson, Per-OlaSahlgrens University Hospital, Sweden (författare)
Haggstrom, JohanKalmar Hospital, Sweden (författare)
Aldrin, AndersVisby Hospital, Sweden (författare)
Hansson, LottaKarolinska Institutet (författare)
Karolinska InstitutetKarolinska University Hospital, Sweden; Karolinska Institute, Sweden (creator_code:org_t)

Av författaren/redakt...: Norin, Stefan; Bjorkstrand, Bo; Rommel, Franz; Timberg, Lars; Andersson, Per-O ...; Haggstrom, Johan; visa fler...; Aldrin, Anders; Hansson, Lotta; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Hematologi

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.